SCHEMBL7128403

SCHEMBL7128403

Nc1cccc(Nc2noc3c(Br)cccc23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 7/20 0.45
AHR P35869 1/20 0.45
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
GFER P55789 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
EGFR P00533 5/20 0.40
ERBB2 P04626 1/20 0.39
SYK P43405 1/20 0.39
KIT P10721 1/20 0.38
RAPGEF4 Q8WZA2 1/20 0.38
RET P07949 1/20 0.38
KDR P35968 1/20 0.38
BACE1 P56817 1/20 0.38
BACE2 Q9Y5Z0 1/20 0.38
NOX4 Q9NPH5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7122006 0.80 EPHX2 (0.54) EPHX2AHRKDM4EMEN1LMNA
SCHEMBL7125011 0.79 ABCG2 (0.52) KDM4EMEN1GAAMAPTKMT2A
SCHEMBL7115895 0.78 EPHX2 (0.71) EPHX2AHRKDM4EMEN1LMNA
SCHEMBL7126041 0.76 EPHX2 (0.43) EPHX2KDM4EMEN1MAPTKMT2A
SCHEMBL7128312 0.72 AHR (0.52) AHRKDM4EMEN1LMNAGAA
SCHEMBL14837965 0.71 IDO1 (0.38) KDM4EMEN1MAPTKMT2ATDP1
SCHEMBL6922978 0.70 ABCG2 (0.49) EPHX2KDM4EMEN1LMNAKMT2A
SCHEMBL21438291 0.69 SMN1; SMN2 (0.40) EPHX2KDM4EMEN1LMNAMAPT
SCHEMBL2127990 0.68 MAPT (0.86) AHRKDM4EMEN1LMNAGAA
SCHEMBL16006559 0.68 KEAP1 (0.38) KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 EPHX2 354/4885AHR 272/4885KDM4E 2224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.